Presentations & Publications

We are proud of our scientific progress, much of which has been documented via various presentations and publications.

Since 2011, our proprietary platform has enabled the design of three new clinical drug candidates, resulting in four clinical programs. Our scientific progress has been documented in various national and international presentations and publications.

December 2019	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients With Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia Dr. David Kuter et al. ASH December 7th, 2019.
October 2019	FC04.08 TIP – A Randomized, Double-Blind, Placebo and Active Controlled, Global Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor PRN1008 in Moderate to Severe Pemphigus Dr. Dedee Murrell et al. EADV October 10th, 2019.
September 2019	Preclinical Mechanisms of Action of PRN1008, a Reversible Covalent Bruton’s Tyrosine Kinase Inhibitor in Clinical Development for Pemphigus Langrish C L, Francesco M R, Xing Y, Bradshaw J M, Owens T D, and Nunn P A. Presented at the 49th annual meeting of the European Society for Dermatological Research (ESDR), September 2019.
May 2019	A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC) Piha-Paul S A, Hierro C, Matos I, Boni V, Hahn N, Bitting R, Bauer T, Aggarwal R, Gourlay S G, Meric-Bernstam F, Owens T D, Brameld K, Neale A, Schwartz R, Murray S, Foote P, Ucpinar S, Tabernero J. Presented at The American Association for Cancer Research Bladder Cancer: Transforming the Field, May 2019.
February 2019	Phase 1 Clinical Trial of PRN2246 (SAR442168), a Covalent BTK Inhibitor Demonstrates Safety, CNS Exposure and Therapeutic Levels of BTK Occupancy Smith P F, Redfern A, Shu J, Xing Y, Hartmann S, Francesco M R, Langrish C L, Burns R, Neale A, Owens T D, Gourlay S G. Presented at Americas Committee for Treatment and Research in Multiple Sclerosis – Forum 2019, February 2019
October 2018	Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity Basler M, Lindstrom MM, LaStant JJ, Bradshaw JM, Owens TD, Schmidt C, Maurits E, Tsu C, Overkleeft HS, Kirk CJ, Langrish CL, Groettrup M. EMBO Reports, October 2018
February 2018	PRN473, an inhibitor of Bruton’s tyrosine kinase, inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling Herter JM, Margraf A, Volmering S, Correia BE, Bradshaw JM, Bisconte A, Hill RJ, Langrish CL, Lowell CA, Zarbock A. British Journal of Pharmacology, February 2018
February 2018	Clinical endpoint analysis of the Believe-PV phase 2 study of PRN1008 in pemphigus Murrell D. F, Stavroupoulos P, Patsatsi A, Baum S, Roussaki A, Kern J.S, Zeeli T, Werth V.P, Gourlay S, Joly P. Presented at Medical Dermatology Society– 2018 Annual Meeting, February 2018

Advancing Promising Therapies

See Our Pipeline